Business Performance Review
R&D Capabilities
Cumulative Filing Status
R&D Spend
(In Millions)
North
Therapy
Europe
Japan
Brazil Australia
ROW
Total
America
R&D Spend
CVS
37
31
4
21
10
33
136
As % to Sales
CNS
36
22
8
13
2
14
95
3.1%
Diabetes
9
5
8
12
34
3.0%
Pain Management
1
2
4
1
8
16
2.7%
2.6%
Others
74
35
6
30
8
55
208
652
Total
157
95
18
76
21
122
489
2.1%
572
400
405
367
•
DMF/CEPS filing continues across major markets in Q2FY24, taking the total cumulative filings to 489 as on 30
Sep, 2023.
3 new products added to the grid of which 1 is High potent API (HP API) / oncology molecule and 2 are
synthetic small molecules.
The HP API portfolio now extends to 12 products with an addressable market of $21bn (Source: IQVIA, MAT
June 23). 3 products are validated and 3 products are in advanced stage of development.
Development progressing well for new iron complex added last quarter to the existing grid of 3 molecules,
each backed by customer interest. Filing completed for 1 iron complex with 2 others in advanced stages of
development. Total addressable market of $1.8 bn (Source: IQVIA, MAT June 23).
FY20
FY21
FY22
FY23
H1 FY24
14
Є Glenmark
LIFE SCIENCESView entire presentation